Inhibitors of Factor VIIa/tissue factor.
The formation of the proteolytic complex composed of the serine protease Factor VIIa and the cell-associated glycoprotein tissue factor (FVIIa/TF) initiates a cascade of amplified zymogen activation reactions leading to thrombus formation. The critical role of the coagulation cascade in pathological thrombosis has been the basis for significant efforts to design selective inhibitors of the protease components as new anticoagulant alternatives for the treatment of thrombotic diseases. However, for the new generation of anticoagulant drugs in development that primarily target protease complexes distal from FVIIa/TF, the differential between efficacy and safety as defined by bleeding is unresolved. Targeting the FVIIa/TF complex has several theoretical advantages that exploit the amplified nature of the coagulation cascade. However, progress on the development of clinical-stage FVIIa/TF-based anticoagulants has not been as successful to date. This review summarizes recent efforts in the discovery of synthetic inhibitors of FVIIa/TF.
Shirk
Rebecca A
RA
Department of Cardiovascular and Metabolic Diseases Research, Wyeth Research, P.O. Box 42528, Philadelphia, PA 19101-2528, USA. shirkr@wyeth.com
Vlasuk
George P
GP
D000925:Anticoagulants / Q000737:chemistry / Q000494:pharmacology; D015195:Drug Design; D015942:Factor VIIa / Q000037:antagonists & inhibitors*; D006801:Humans; D015842:Serine Proteinase Inhibitors / Q000737:chemistry / Q000494:pharmacology; D013925:Thromboplastin / Q000037:antagonists & inhibitors*
D000925:Anticoagulants; D015842:Serine Proteinase Inhibitors; D013925:Thromboplastin; D015942:Factor VIIa